Goldman Sachs
CLYM

Goldman Sachs’s Climb Bio CLYM Stock Holding History

Goldman Sachs’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Sell
149,970
-74,913
-33% -$432K ﹤0.01% 5069
2025
Q4 		$900K Buy
224,883
+151,168
+205% +$363K ﹤0.01% 5215
2025
Q3 		$148K Sell
73,715
-127,597
-63% -$237K ﹤0.01% 6008
2025
Q2 		$250K Buy
201,312
+80,570
+67% +$100K ﹤0.01% 5547
2025
Q1 		$147K Sell
120,742
-4,562
-4% -$7.4K ﹤0.01% 5707
2024
Q4 		$226K Buy
125,304
+66,258
+112% +$240K ﹤0.01% 5598
2024
Q3 		$301K Buy
+59,046
New +$418K ﹤0.01% 5297
2022
Q3 		– Sell
-162,792
Closed -$492K – 6582
2022
Q2 		$492K Sell
162,792
-2,295
-1% -$10.9K ﹤0.01% 5091
2022
Q1 		$1.39M Buy
165,087
+964
+0.6% +$8.99K ﹤0.01% 4562
2021
Q4 		$1.72M Sell
164,123
-1,829
-1% -$27.3K ﹤0.01% 4379
2021
Q3 		$2.98M Buy
+165,952
New +$3.43M ﹤0.01% 3820

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Goldman Sachs's CLYM Position: Q1 2026 in Review

Goldman Sachs reduced its Climb Bio (CLYM) stake by 33% in Q1 2026, selling an estimated $432K and leaving 149,970 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #5069.

Goldman Sachs first reported a position in CLYM in Q3 2021 and has held it in 11 quarters since. The position peaked at $2.98M in Q3 2021. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Goldman Sachs held 149,970 shares of Climb Bio worth $1.03M as of Q1 2026.
  • Goldman Sachs sold 74,913 Climb Bio shares in Q1 2026, an estimated $432K.
  • Climb Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5069 holding.
  • Goldman Sachs first reported a position in Climb Bio in Q3 2021 and has held it in 11 quarters since.
  • Goldman Sachs's Climb Bio position peaked at $2.98M in Q3 2021.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.